



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/088 (10-01)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of

Complete if Known

Application Number	09/506,430
Filing Date	February 17, 2000
First Named Inventor	Green, Lawrence R.
Art Unit	1653
Examiner Name	Lukton, David
Attorney Docket Number	015542-002330US

RECEIVED
MAY 10 2002
CENTRAL MAIL ROOM

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>DL</i>	AK	Daly, T. J. et al., "High Activity Suppression of Myeloid Progenitor Proliferation by Chimeric Mutants of Interleukin 8 and Platelet Factor 4," The Journal of Biological Chemistry, Vol. 270, No. 40, October 6, 1995, pp. 23282-23292.	
<i>I</i>	AL	DATABASE WPI, Section Ch, Week 9212, Derwent Publications Ltd., London, GB; Class B04, AN 92-094519, XP002023101 & SU, A, 1 642 398 (ROST MED INST), 15 April 1991. Abstract Only	
<i>I</i>	AM	DATABASE WPI, Section Ch, Week 9501, Derwent Publications Ltd., London, GB; Class B05, AN 95-004962, XP002023100 & SU, A, 1 827 255 (KIEV DOCTOR TRAINING INST), 15 July 1993. Abstract Only.	
<i>I</i>	AN	DATABASE WPI, Section Ch, Week 9511, Derwent Publications Ltd., London, GB; Class B05, AN 95-080267, XP002023102 & RU, C, 2 014 063 (SOCHI SPAS PHYSIOTHERAPY RES INST), 15 June 1994. Abstract Only.	
<i>I</i>	AO	Folkman, J., "What Is the Evidence That Tumors Are Angiogenesis Dependent?," Journal of the National Cancer Institute, Vol. 82, No. 1, January 3, 1990, pp. 4-6.	
<i>I</i>	AP	Frater-Schroder et al., "Tumor necrosis factor type α , a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo," Proc. Natl. Acad. Sci. USA, Vol. 84, August 1987, pp. 5277-5281.	
<i>I</i>	AQ	Heimark, R.L. et al., "Inhibition of Endothelial Regeneration by Type-Beta Transforming Growth Factor from Platelets," Science, Vol. 233, September 5, 1986, pp. 1078-1080.	
<i>DL</i>	AR	Kahn, J.O. et al., "Intralesional Recombinant Tumor Necrosis Factor- α for AIDS-Associated Kaposi's Sarcoma: A Randomized, Double-Blind Trial," Journal of Acquired Immune Deficiency Syndromes, Vol. 2, No. 3, (1989) pp. 217-223.	
<i>DL</i>	AS	Knighton, D. et al., "Avascular And Vascular Phases Of Tumor Growth In The Chick Embryo," Br. J. Cancer, Vol. 35, pp. 347-336	
<i>X</i>	AT	Maione, T.E., "Direct Clinical Applications of Chemokines," IBC Conference "Chemotactic Cytokines" October 26, 1995	
<i>X</i>	AU	Maione, T.E. et al., "Development of angiogenesis inhibitors for clinical applications," Trends in Pharmaceutical Sciences, Vol. 11, November 1990, pp. 457-460.	
<i>DL</i>	AV	Nakamura, S. et al., "Kaposi's Sarcoma Cells: Long-Term Culture with Growth Factor from Retrovirus-Infected CD4+ T Cells," Science, Vol. 242, October 21, 1988, pp. 426-430.	
<i>X</i>	AW	Rodionov et al., "The Immunocorrective Therapy of Pyoderma Caused by Staphylococci Multiply Resistant to Antibiotics," Vestn. Dermatol. Venerol, Vol. 1, (Medline Abstract No. 90224329) (1990) pp. 42-45.	<i>X</i>
<i>DL</i>	AX	Sidky, Y.A. et al., "Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses," Cancer Research, Vol. 47, October 1, 1987, pp. 5155-5161.	
<i>DL</i>	AY	Wiseman, D.M. et al., "Transforming Growth Factor-Beta (TGF β) Is Chemotactic For Human Monocytes And Induces Their Expression of Angiogenic Activity," Biochemical and Biophysical Research Communications, Vol. 157, No. 2, December 15, 1988, pp. 793-800.	

Examiner Signature	<i>David Lukton</i>	Date Considered	<i>6/5/02</i>
--------------------	---------------------	-----------------	---------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1340794 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

Application Number

09/506,430

Filing Date

February 17, 2000

First Named Inventor

Green, Lawrence R.

Art Unit

1653

Examiner Name

Lukton, David

Attorney Docket Number

015542-002330US

Complete if Known

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DL	AA	US-4,191,753	03/04/1980	Ryan	424-177
	AB	US-5,100,873	03/31/1992	de Castiglione et al.	514-15
	AC	US-5,538,951	07/23/1996	Morozov et al.	514-19
	AD	US-5,728,680	03/17/1998	Morozov et al.	514-19
	AE	US-5,767,087	06/16/1998	Morozov et al.	514-19
	AF	US-5,770,576	06/23/1998	Morozov et al.	514-19

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
DL	AG	WIPO	WO 89/06134	07/13/1989			
	AH	WIPO	WO 92/17191	10/15/1992			
	AI	WIPO	WO 93/08815	05/13/1993			
DL	AJ	WIPO	WO 95/03067	02/02/1995			

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1340794 v1